Simon Rule, MD from Plymouth University, Plymouth, UK shares his highlights from the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. Prof. Rule begins by explaining some encouraging data presented by Michael Wang, including high remission rates following front-line treatment with ibrutinib combined with rituximab. Providing more examples of interesting trial data presented at the meeting, Prof. Rule discusses the idea of lymphoma treatment moving towards combination therapies as opposed to single-agent therapy.
This video was supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. The company had no influence on the production of this content.